| | |
Metabolic syndrome OR(95% CI).
|
HOMA-IR ≥2.6† OR(95% CI).
|
|---|
| | |
Tertile of hsCRP
|
Tertile of GGT
|
Tertile of hsCRP
|
Tertile of GGT
|
|---|
| | |
1st
|
2nd
|
3rd
|
1st
|
2nd
|
3rd
|
1st
|
2nd
|
3rd
|
1st
|
2nd
|
3rd
|
|---|
|
Characteristics
| |
<0.360
|
0.360-0.800
|
>0.800 mg/L
|
<29
|
29-54
|
>54 IU/L
|
<0.280
|
0.280-0.650
|
>0.650 mg/L
|
<18
|
18-24
|
>24 IU/L
|
|---|
|
Age
| | | | | | | | | | | | | |
|
<65 years
|
650
|
1.00
|
2.13 (1.26-3.59)
|
3.76 (2.25-6.27)
|
1.00
|
2.66 (1.50-4.72)
|
3.55 (2.00-6.31)
|
1.00
|
2.50 (1.44-4.33)
|
4.50 (2.62-7.72)
|
1.00
|
2.47 (1.37-4.45)
|
3.04 (1.70-5.42)
|
|
≥65 years
|
969
|
1.00
|
1.21 (0.73-2.03)
|
1.88 (1.16-3.06)
|
1.00
|
1.84 (1.12-3.04)
|
3.80 (2.31-6.28)
|
1.00
|
2.16 (1.12-4.15)
|
3.87 (2.08-7.19)
|
1.00
|
2.16 (1.12-4.15)
|
3.87 (2.08-7.19)
|
|
Alcohol consumption
| | | | | | | | | | | | | |
|
Absent
|
829
|
1.00
|
1.42 (0.83-2.44)
|
2.27 (1.34-3.85)
|
1.00
|
1.94 (1.16-3.25)
|
3.04 (1.78-5.10)
|
1.00
|
1.11 (0.62-1.98)
|
2.23 (1.29-3.87)
|
1.00
|
4.72 (2.47-9.03)
|
7.41 (3.81-14.4)
|
|
Present
|
1090
|
1.00
|
1.74 (1.07-2.84)
|
2.91 (1.82-4.66)
|
1.00
|
2.65 (1.54-4.58)
|
4.89 (2.83-8.44)
|
1.00
|
4.50 (2.37-8.54)
|
7.30 (3.88-13.7)
|
1.00
|
1.62 (0.93-2.82)
|
2.66 (1.55-4.55)
|
|
Uric acid
| | | | | | | | | | | | | |
|
<5.0 (mean) mg/dL
|
978
|
1.00
|
1.51 (0.87-2.60)
|
3.21 (1.90-5.40)
|
1.00
|
2.39 (4.41-4.05)
|
3.53 (2.07-6.03)
|
1.00
|
1.98 (1.11-3.54)
|
3.57 (2.03-6.29)
|
1.00
|
2.79 (1.59-4.89)
|
3.46 (1.95-6.14)
|
|
≥5.0 (mean) mg/dL
|
941
|
1.00
|
1.68 (1.03-2.75)
|
2.14 (1.33-3.44)
|
1.00
|
2.24 (1.32-3.79)
|
4.04 (2.38-6.85)
|
1.00
|
1.68 (1.03-2.75)
|
2.14 (1.33-3.44)
|
1.00
|
2.24 (1.32-3.79)
|
4.04 (2.38-6.85)
|
|
HMW adiponectin
| | | | | | | | | | | | | |
|
<5.03 (median) μg/mL
|
963
|
1.00
|
1.64 (1.02-2.64)
|
2.74 (1.73-4.32)
|
1.00
|
2.63 (1.63-4.23)
|
3.52 (2.18-5.69)
|
1.00
|
2.63 (1.50-4.60)
|
4.57 (2.66-7.87)
|
1.00
|
1.86 (1.11-3.09)
|
3.23 (1.97-5.30)
|
|
≥5.03 (median) μg/mL
|
956
|
1.00
|
1.27 (0.71-2.27)
|
1.53 (0.85-2.75)
|
1.00
|
1.79 (0.96-3.34)
|
3.76 (2.04-6.96)
|
1.00
|
1.61 (0.84-3.10)
|
2.12 (1.11-4.05)
|
1.00
|
4.41 (2.07-9.42)
|
5.09 (2.33-11.1)
|
|
Medication‡
| | | | | | | | | | | | | |
|
Absent
|
1342
|
1.00
|
1.76 (1.09-2.85)
|
3.11 (1.95-4.93)
|
1.00
|
2.02 (1.23-3.31)
|
3.36 (2.06-5.50)
|
1.00
|
3.24 (1.87-5.62)
|
5.73 (3.34-9.84)
|
1.00
|
2.39 (1.43-3.97)
|
3.05 (1.84-5.07)
|
|
Present
|
577
|
1.00
|
1.18 (0.66-2.09)
|
1.87 (1.07-3.25)
|
1.00
|
2.22 (1.24-3.96)
|
3.55 (1.95-6.44)
|
1.00
|
1.12 (0.57-2.19)
|
2.07 (1.10-3.88)
|
1.00
|
2.94 (1.43-6.06)
|
6.09 (2.94-12.6)
|
- Metabolic syndrome was defined as having three or more of the following conditions: obesity, raised blood pressure, hypertriglyceridemia, low HDL cholesterolemia, and impaired fasting blood glucose. † Insulin resistance was defined as HOMA-IR ≥2.6. ‡Medication was defined as antihypertensive, antilipidemic, or diabetic medication. Each tertile was calculated within sex and then combined to avoid the gender differences. Values adjusted for sex, age, smoking status, alcohol consumption, uric acid, and estimated glomerular filtration rate.
